LCZ696, a combination of Sacubitril and Valsartan, has a cardio-protective effect against myocardial infarction
The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac death and hospitalization due to heart failure.
Now, researchers from Kumamoto University in Japan have revealed that LCZ696 can prevent cardiac rupture and heart failure following acute myocardial infarction which is one of the causes of chronic heart failure.
Heart disease is the leading cause of death in the world, and the majority of those deaths are caused by heart failure and acute myocardial infarction.
In the past, angiotensin converting enzyme inhibitors ( ACE inhibitors ) or Angiotensin II Receptor Blockers ( ARBs;sartans ) were used in combination with other drugs as the initial therapy for heart failure and acute myocardial infarction.
ACE inhibitors and sartans both inhibit the system responsible for regulating blood pressure, the RAAS ( Renin-Angiotensin-Aldosterone System ), which causes high blood pressure when it becomes overactive.
LCZ696 is a novel drug that combines Valsartan, a traditional antihypertensive drug, and Sacubitril, which has an organ-protective effect.
Sacubitril inhibits neprilysin which decomposes hormones secreted mainly from the heart called atrial natriuretic peptide ( ANP ), and B-type natriuretic peptide ( BNP ).
A 2014 large-scale clinical trial of patients who had chronic heart failure with reduced ejection fraction reported that the number of cardiac deaths and re-hospitalizations due to heart failure was reduced significantly with LCZ696 treatment than with existing ACE inhibitors.
LCZ696 is now used in Europe and the United States as the first treatment for chronic heart failure.
LCZ696 was established as a chronic heart failure treatment because it suppresses RAAS action and enhances the function of the natriuretic peptide system, which protects the heart.
However, it is not yet clear whether it is useful in the acute phase of acute myocardial infarction, which causes chronic heart failure.
In a myocardial infarction, the wall between the necrotic and non-necrotic areas of the heart is torn causing rupture and bleeding at the boundary.
Ten percent of deaths from myocardial infarction is attributed to cardiac rupture.
Therefore, researchers examined the effect of LCZ696, using an artificial myocardial infarction mouse model ( a wild-type mouse ).
The day after the myocardial infarction model mice were created, they were divided into groups that (1) did not receive any treatment ( control group ), (2) received an ACE inhibitor, and (3) received LCZ696.
The researchers found that the mortality rate due to cardiac rupture occurring within one week after myocardial infarction was significantly lower in the LCZ696 treatment group than in the other two groups.
Gene expression in the area of myocardial infarction was analyzed to investigate the mechanism that LCZ696 could inhibit cardiac rupture.
The researchers found that the expression of genes involved in inflammation-related cytokines ( IL-1 beta, IL-6 ) and in tissue degrading MMP-9 was clearly reduced in the LCZ696 treatment group.
An increase in the function of the MMP-9 gene is known to be related to the cause of cardiac rupture.
In addition, microscopic observations of the pathological tissue of the heart showed that the number of inflammatory cells was unchanged in all groups, but the activity of MMP-9 was clearly lowered in the LCZ696 treatment group.
Furthermore, in experiments using cultured mouse macrophages, researchers confirmed that the inflammation action of cytokines and MMP-9 can be more suppressed using LCZ696 rather than using Valsartan or Sacubitril by themselves.
Research results were presented at the European Cardiology Society ( ESC ) Congress 2017 held in Barcelona, Spain, and posted in the JACC; Basic to Translational Science. ( Xagena )
Source: Kumamoto University, 2017
The FDA ( US Food and Drug Administration ) has approved the following expanded indication for Entresto ( Sacubitril /...
SARS-CoV-2 uses the angiotensin-converting enzyme ( ACE ) 2 receptor for entry into target cells. ACE2 is predominantly expressed by...
Canagliflozin reduces major cardiovascular events and kidney failure in patients with type 2 diabetes and chronic kidney disease
Results of a new subgroup analysis from the phase 3 CREDENCE study, showing Canagliflozin ( Invokana ) has significantly reduced...
PARAGON-HF trial in heart failure patients with preserved ejection fraction: Entresto misses statistical significance on the primary endpoint
The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto...
Entresto, a combination of Sacubitril and Valsartan, can be initiated early in hospitalized patients after an acute heart failure episode
Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...
The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...
Hypertension is a common diabetes comorbidity that affects the majority of patients, with the prevalence depending on type of diabetes,...
Angiotensin-converting enzyme inhibitors and receptor blockers were associated with significant lower incidence of appropriate ICD shock in patients with cardiomyopathy
Sudden cardiac death ( SCD ) is a leading cause of mortality in patients with cardiomyopathy. Although angiotensin-converting enzyme inhibitors...
Angiotensin converting enzyme inhibitors ( ACE inhibitors ) and angiotensin receptor blockers ( ARBs; sartans ) are widely prescribed for...